This 185-page report, “Global Pharmaceutical Manufacturing Market 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity,” is highlighted by 85 tables and 96 figures and is based on extensive research of the entire global pharmaceutical manufacturing industry and all of its sub-segments. Premium primary and secondary information sources are used to create in-depth research and assessment, with input coming from business specialists working across the value chain.
The COVID-19 pandemic, rising prevalence of chronic illnesses, growing geriatric population, high investment in research and development, and rising per capita healthcare costs will all contribute to the global pharmaceutical manufacturing industry’s projected $673.6 billion revenue by 2027, an increase of 12.5% annually over 2020-2027.
The Pharmaceutical Manufacturing Market report uses 2019 as the base year and includes estimates and forecasts for 2020 through 2027 based on studies from 2017 to 2019. (Please note that the report will be updated before to delivery to ensure that the forecast includes at least 5 years past the base year and the most recent historical year serves as the base year.)
The following aspects are identified and examined in-depth qualitative analyses:
Porter’s Five Forces: Industry Structure, Growth Drivers, Obstacles and Challenges, Emerging Product Trends and Industry Opportunities
By taking COVID-19 into consideration, the trend and outlook of the global industry are predicted from an upbeat, fair, and conservative perspective. The global pharmaceutical manufacturing sector is quantified from all angles, including formulation, route of administration, age group, therapeutic application, drug type, distribution channel, production facility, and region, using the balanced (most likely) projection.
Request Research Sample with Latest Industry Insights (185+ Pages Report): https://altusmarketresearch.com/reports/sample/3419
The following sub-markets are used to segment the global industry based on formulation, and each section includes the annual production value for 2017–2027.
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations
Based on Route of Administration, the global Pharmaceutical Manufacturing Market is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Oral Medicine
• Topical Medicine
• Parenteral Medicine
• Inhalations
• Other Routes of Administration
Based on Age Group, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Children & Adolescents
• Adults
• Geriatric
Based on Therapeutic Application, the global Pharmaceutical Manufacturing Market is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Cardiovascular Diseases
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Neurological Diseases
• Orthopedics
• Other Applications
Based on Drug Type, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Based on Distribution Channels, the global Pharmaceutical Manufacturing Market is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Retail Channels
• Non-retail Channels
Based on Manufacturing Facility, the global industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• In-house Facility
• Outsourced Facility
Along with the listed national/local markets, the following geographic areas are thoroughly investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
In Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• America, North (U.S., Canada, and Mexico)
Latin America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa) (UAE, Saudi Arabia, South Africa)
There are thorough analyses and data for annual production value for each of the aforementioned regions and nations for the years 2017 through 2027. All regional markets are broken down by country, and the important national industries are divided by drug type, route of administration, and formulation during the course of the anticipated years.
The research also analyses the present competitive landscape, the anticipated trend, and it provides profiles of prominent vendors, including both established leaders in their fields and significant up-and-coming companies.
Through AMR’s Risk Assessment System, possible risks related to investments in the global pharmaceutical manufacturing business are specifically assessed quantitatively and qualitatively. Critical Success Factors (CSFs) are developed based on the risk analysis and evaluation as a guide to assist investors and stockholders in identifying emerging possibilities, managing and minimising risks, developing suitable business models, and making informed strategies and decisions.
Key Players (this list may not be exhaustive; additional businesses can be included upon request):
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda
